26 Oct The New Frontier: Peptide Therapies for Autoimmune Disease
If you’ve spent time online looking for help with inflammation, fatigue, or joint pain, you’ve probably seen peptide therapy advertised as the answer.
Our honest take: peptides are a real area of medical research. But there’s a wide gap between what scientists are studying and what websites are selling.
What Peptides Actually Are
Peptides are very small proteins. Your body makes them constantly and uses them as messengers — they tell cells what to do, help control the immune system, and help direct tissue repair.
That messenger role is exactly why researchers find them interesting for autoimmune disease, where the immune system misreads its own signals and attacks healthy tissue.
Peptides are not fringe medicine. Some are FDA-approved and prescribed every day. Two osteoporosis drugs, teriparatide and abaloparatide, are peptides. So are the newer diabetes and weight medications you’ve been hearing about. The question isn’t whether peptides can work as medicine — they can. It’s whether the particular ones being sold online have proven they work.
What Researchers Are Actually Studying
Thymosin alpha-1 has been around longest and is used in some countries outside the U.S. to help regulate the immune system. Whether it helps autoimmune arthritis is still unknown.
KPV is a small piece of a natural hormone. It has reduced inflammation in laboratory and animal studies, but hasn’t been properly tested in people.
BPC-157 and TB-500 are the two you’ll see promoted most for healing and tissue repair. Nearly all the evidence comes from animal studies. Neither has completed a human trial for any condition.
LL-37 deserves a warning. Some websites list it as a peptide treatment for autoimmune disease. Research points the opposite way. In psoriasis, psoriatic arthritis, and lupus, LL-37 appears to be one of the things the immune system mistakenly attacks — meaning it may help fuel inflammation rather than calm it.
Where the Law Stands Right Now
Peptide rules changed a lot in 2026.
In April, the FDA took BPC-157 and several other peptides off a restricted list that had kept pharmacies from preparing them. In July, an FDA advisory panel voted to recommend six peptides — including BPC-157, TB-500, and KPV — for a list that would allow pharmacies to compound them.
Worth knowing: the FDA’s own scientists reviewed those same peptides and recommended against all of them, saying there wasn’t enough evidence on safety or whether they actually work. The advisory panel voted the other way. The FDA hasn’t issued a final decision.
None of this is FDA approval. No peptide is approved to treat rheumatoid arthritis, lupus, psoriatic arthritis, or ankylosing spondylitis.
What This Means for You
To be clear: peptides will not cure autoimmune disease, undo joint damage you already have, or replace the medications that control your condition.
Products sold online carry genuine risks:
- You don’t know what’s actually in the vial
- Dosing is guesswork
- They can interact with your prescriptions
- Some may stir up immune activity instead of quieting it
If peptide therapy interests you, bring it to your next visit instead of ordering from a website. That can be in person or by telemedicine. We’d rather talk it through with you than find out afterward.
We do offer infusion treatments with real evidence behind them, and we’re glad to explain the difference.
At Island Rheumatology & Osteoporosis, you’ll get a straight answer about what the evidence shows — the same way we handle diet claims like the nightshade myth — and we’ll make sure anything new doesn’t undercut the treatment already protecting your joints. Request an appointment to talk it over.
